Skip to main content
Erschienen in: Familial Cancer 1/2011

01.03.2011

Sharing genetic risk with next generation: mutation-positive parents’ communication with their offspring in Lynch Syndrome

verfasst von: Katja I. Aktan-Collan, Helena A. Kääriäinen, Eeva M. Kolttola, Kirsi Pylvänäinen, Heikki J. Järvinen, Ari H. Haukkala, Jukka-Pekka Mecklin

Erschienen in: Familial Cancer | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Identification of hereditary predisposition to cancer has limited significance if not followed by efficient cancer prevention. The responsibility of informing offspring about genetic risk often falls to the parents. We systematically investigated how parents with Lynch Syndrome share knowledge of genetic risk with their offspring, challenges in the communication process and wish for professional support. Of all known mutation carriers over age 40 (n = 337) in 102 Finnish Lynch Syndrome families, 86% completed a self-reported questionnaire; 248 of them (86%) had children. Of the 248 parents, 87% reported disclosure and 13% nondisclosure. Reasons for nondisclosure were mainly the young age of offspring, socially distant relationships, or feeling of difficulty in discussing the topic. Men reported significantly more often disclosure with a support person (spouse etc.) (P < 0.001). The most difficult communication aspect was discussing children’s cancer risk. Of the 191 firstborn adult children informed, 69% had taken the predictive genetic test. Every third parent suggested that health professionals should be involved in passing on the information and that a family appointment at the genetic clinic should be organized at the time of disclosure. Nearly all parents had informed their adult offspring about the genetic risk and possibility of genetic testing, but almost one-third were unsure of how their offspring had used the information. The challenge is to improve the communication processes, so that all offspring would get the information important for their health care, and parents would get the professional support desired at disclosure.
Literatur
1.
2.
Zurück zum Zitat Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027CrossRefPubMed Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027CrossRefPubMed
3.
Zurück zum Zitat Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218CrossRefPubMed Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218CrossRefPubMed
4.
Zurück zum Zitat Järvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al (2009) Ten years after mutation testing for Lynch Syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797CrossRefPubMed Järvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al (2009) Ten years after mutation testing for Lynch Syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797CrossRefPubMed
5.
Zurück zum Zitat De Jong AE, Hendriks YMC, Kleibeuker JH et al (2006) Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665–671CrossRefPubMed De Jong AE, Hendriks YMC, Kleibeuker JH et al (2006) Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665–671CrossRefPubMed
6.
Zurück zum Zitat Claes E, Evers-Kiebooms G, Boogaerts A et al (2003) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A116:11–19CrossRef Claes E, Evers-Kiebooms G, Boogaerts A et al (2003) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A116:11–19CrossRef
7.
Zurück zum Zitat Hughes C, Lerman C, Schwartz M et al (2002) All in the family: evaluation of the process and content of sisters’ communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet 107:143–150CrossRefPubMed Hughes C, Lerman C, Schwartz M et al (2002) All in the family: evaluation of the process and content of sisters’ communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet 107:143–150CrossRefPubMed
8.
Zurück zum Zitat Segal J, Esplen B, Toner B et al (2004) An investigation of the disclosure process and support need of BRCA1 and BRCA2 carriers. Am J Med Genet A125:267–272CrossRef Segal J, Esplen B, Toner B et al (2004) An investigation of the disclosure process and support need of BRCA1 and BRCA2 carriers. Am J Med Genet A125:267–272CrossRef
9.
Zurück zum Zitat Gaff CL, Clarke JA, Atkinson P et al (2007) Process and outcome in communication of genetic information within families: a systematic review. Eur J Hum Genet 15:999–1011CrossRefPubMed Gaff CL, Clarke JA, Atkinson P et al (2007) Process and outcome in communication of genetic information within families: a systematic review. Eur J Hum Genet 15:999–1011CrossRefPubMed
10.
Zurück zum Zitat DeMarco TA, McKinnon WC (2007) Life after BRCA1/2 testing: family communication and support issues. Breast Dis 27:127–136 DeMarco TA, McKinnon WC (2007) Life after BRCA1/2 testing: family communication and support issues. Breast Dis 27:127–136
11.
Zurück zum Zitat Chivers Seymour K, Addington-Hall J, Lucassen AM et al (2010) What facilitates or impedes family communication following genetic testing for cancer Risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns [Epub ahead of print, 9 Apr 2010] Chivers Seymour K, Addington-Hall J, Lucassen AM et al (2010) What facilitates or impedes family communication following genetic testing for cancer Risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns [Epub ahead of print, 9 Apr 2010]
12.
Zurück zum Zitat Peterson SK, Watts B, Koehly LM et al (2003) How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet 119C:78–86CrossRefPubMed Peterson SK, Watts B, Koehly LM et al (2003) How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet 119C:78–86CrossRefPubMed
13.
Zurück zum Zitat Mesters I, Ausems M, Eichhorn S et al (2005) Informing one’s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer 4:163–167CrossRefPubMed Mesters I, Ausems M, Eichhorn S et al (2005) Informing one’s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer 4:163–167CrossRefPubMed
14.
Zurück zum Zitat Carlsson C, Nilbert M et al (2007) Living with hereditary non-polyposis colorectal cancer; experiences from and impact of genetic testing. J Genet Couns 16:811–820CrossRefPubMed Carlsson C, Nilbert M et al (2007) Living with hereditary non-polyposis colorectal cancer; experiences from and impact of genetic testing. J Genet Couns 16:811–820CrossRefPubMed
15.
Zurück zum Zitat Gaff CL, Collins V, Symes T et al (2005) Facilitating family communication about predictive genetic testing: probands’ perceptions. J Genet Couns 14:133–140CrossRefPubMed Gaff CL, Collins V, Symes T et al (2005) Facilitating family communication about predictive genetic testing: probands’ perceptions. J Genet Couns 14:133–140CrossRefPubMed
16.
Zurück zum Zitat Stoffel EM, Ford B, Mercado RC et al (2008) Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol 6:333–338CrossRefPubMed Stoffel EM, Ford B, Mercado RC et al (2008) Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol 6:333–338CrossRefPubMed
17.
Zurück zum Zitat Pylvänäinen K, Kairaluoma M et al (2006) Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer 5:175–178CrossRefPubMed Pylvänäinen K, Kairaluoma M et al (2006) Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer 5:175–178CrossRefPubMed
18.
Zurück zum Zitat Tupasela A (2006) When legal worlds collide: from research to treatment in hereditary cancer prevention. Eur J Cancer Care 15:257–266CrossRef Tupasela A (2006) When legal worlds collide: from research to treatment in hereditary cancer prevention. Eur J Cancer Care 15:257–266CrossRef
19.
Zurück zum Zitat Aktan-Collan K, Mecklin JP, Jarvinen H et al (2000) Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 89:44–50CrossRefPubMed Aktan-Collan K, Mecklin JP, Jarvinen H et al (2000) Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 89:44–50CrossRefPubMed
20.
Zurück zum Zitat Aktan-Collan K, Haukkala A, Kääriäinen H (2001) Life and health insurance behaviour of individuals having undergone a predictive genetic testing programme for hereditary non-polyposis colorectal cancer. Community Genet 4(4):219–224CrossRefPubMed Aktan-Collan K, Haukkala A, Kääriäinen H (2001) Life and health insurance behaviour of individuals having undergone a predictive genetic testing programme for hereditary non-polyposis colorectal cancer. Community Genet 4(4):219–224CrossRefPubMed
21.
Zurück zum Zitat Aktan-Collan K, Haukkala A, Mecklin JP et al (2001) Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet 38:787–792CrossRefPubMed Aktan-Collan K, Haukkala A, Mecklin JP et al (2001) Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet 38:787–792CrossRefPubMed
22.
Zurück zum Zitat Wertz DC, Fanos JH et al (1994) Genetic testing for children and adolescents. Who decides? JAMA 272:875–881CrossRefPubMed Wertz DC, Fanos JH et al (1994) Genetic testing for children and adolescents. Who decides? JAMA 272:875–881CrossRefPubMed
23.
Zurück zum Zitat Metcalfe A, Coad J, Plumridge G et al (2008) Family communication between children and their parents about inherited genetic conditions: a meta-synthesis of the research. Eur J Hum Genet 16:1193–1200CrossRefPubMed Metcalfe A, Coad J, Plumridge G et al (2008) Family communication between children and their parents about inherited genetic conditions: a meta-synthesis of the research. Eur J Hum Genet 16:1193–1200CrossRefPubMed
24.
Zurück zum Zitat Borry P, Evers-Kiebooms G, Cornel MC et al (2009) Genetic testing in asymptomatic minors: background considerations towards ESHG recommendations. Eur J Hum Genet 17(6):711–719CrossRefPubMed Borry P, Evers-Kiebooms G, Cornel MC et al (2009) Genetic testing in asymptomatic minors: background considerations towards ESHG recommendations. Eur J Hum Genet 17(6):711–719CrossRefPubMed
25.
Zurück zum Zitat Pentz RD, Peterson SK, Watts B et al (2005) Hereditary nonpolyposis colorectal cancer family members’ perceptions about the duty to inform and health professionals’ role in disseminating genetic information. Genet Test 9:261–268CrossRefPubMed Pentz RD, Peterson SK, Watts B et al (2005) Hereditary nonpolyposis colorectal cancer family members’ perceptions about the duty to inform and health professionals’ role in disseminating genetic information. Genet Test 9:261–268CrossRefPubMed
26.
Zurück zum Zitat Landsbergen K, Verhaak C, Kraaimaat F et al (2004) Genetic uptake in BRCA mutation carriers is related to emotional and behavioural communication characteristics of index patients. Fam Cancer 4:115–119CrossRef Landsbergen K, Verhaak C, Kraaimaat F et al (2004) Genetic uptake in BRCA mutation carriers is related to emotional and behavioural communication characteristics of index patients. Fam Cancer 4:115–119CrossRef
27.
Zurück zum Zitat Lynch HT, Snyder CL, Lynch JF et al (2009) Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations. Breast J 15(Suppl 1):20–24CrossRef Lynch HT, Snyder CL, Lynch JF et al (2009) Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations. Breast J 15(Suppl 1):20–24CrossRef
28.
Zurück zum Zitat Koehly LM, Peterson SK, Watts BG et al (2003) A social network analysis of communication about hereditary nonpolyposis colorectal cancer genetic testing and family functioning. Cancer Epidemiol Biomarkers Prev 12:304–313PubMed Koehly LM, Peterson SK, Watts BG et al (2003) A social network analysis of communication about hereditary nonpolyposis colorectal cancer genetic testing and family functioning. Cancer Epidemiol Biomarkers Prev 12:304–313PubMed
29.
Zurück zum Zitat Aktan-Collan K, Haukkala A, Pylvänäinen K et al (2007) Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet 44:732–738CrossRefPubMed Aktan-Collan K, Haukkala A, Pylvänäinen K et al (2007) Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet 44:732–738CrossRefPubMed
30.
Zurück zum Zitat Suthers GK, Armstrong J, McCormack J et al (2006) Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet 43:665–670CrossRefPubMed Suthers GK, Armstrong J, McCormack J et al (2006) Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet 43:665–670CrossRefPubMed
31.
Zurück zum Zitat Swendsen MN, Koch L (2006) Genetics and prevention: a policy in the making. New Genetic Soc 5:51–68 Swendsen MN, Koch L (2006) Genetics and prevention: a policy in the making. New Genetic Soc 5:51–68
32.
Zurück zum Zitat Lynch PM (2007) New issues in genetic counselling and testing of hereditary colon cancer. Clin Cancer Res 13:6857–6861CrossRef Lynch PM (2007) New issues in genetic counselling and testing of hereditary colon cancer. Clin Cancer Res 13:6857–6861CrossRef
33.
Zurück zum Zitat Vasen HFA, Möslein G, Alonso A et al (2010) Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 9(2):109–115CrossRefPubMed Vasen HFA, Möslein G, Alonso A et al (2010) Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 9(2):109–115CrossRefPubMed
Metadaten
Titel
Sharing genetic risk with next generation: mutation-positive parents’ communication with their offspring in Lynch Syndrome
verfasst von
Katja I. Aktan-Collan
Helena A. Kääriäinen
Eeva M. Kolttola
Kirsi Pylvänäinen
Heikki J. Järvinen
Ari H. Haukkala
Jukka-Pekka Mecklin
Publikationsdatum
01.03.2011
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2011
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9386-x

Weitere Artikel der Ausgabe 1/2011

Familial Cancer 1/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.